logo-loader
RNS
Halma PLC

Halma PLC - Acquisition

RNS Number : 2198L
Halma PLC
07 July 2026
 

 

Halma plc ('Halma' or the 'Group')

Acquisition

 

Halma plc, the global group of life-saving technology companies, today announces that it has agreed to acquire Dreampath Diagnostics ('Dreampath').

 

Headquartered in Strasbourg, France, Dreampath is the leading provider of automated systems that enable anatomical pathology laboratories to safely and efficiently track, store and manage patient tissue samples throughout the diagnostic process.

 

As international regulation requires samples to be retained for extended periods with a minimum of 10 years, there is a critical need for secure, traceable and scalable storage solutions. By automating largely manual workflows for sample storage, tracking and retrieval, Dreampath's solutions improve traceability, reduce the risk of misidentification and increase operational efficiency in a highly regulated, mission-critical stage of the patient journey, ultimately reinforcing patient safety. Its platform combines hardware, software and a high percentage of recurring revenue consumables in a closed system, to manage the full lifecycle of patient tissue samples.

 

The initial cash consideration is €154m (approximately £132m), on a cash- and debt-free basis, to be funded from Halma's existing facilities. In addition, an earn-out of up to a maximum €121m (approximately £104m) is payable in cash, based on performance over the two years to 31 March 2027 and 2028 (split 38%/62%). Dreampath's revenue for the 12 months to 31 March 2027 is forecast to be €33m (approximately £28m).

 

The acquisition strengthens Halma's Healthcare Sector by adding capabilities in tissue sample traceability, archiving and lifecycle management, complementing its existing portfolio in Healthcare Enablement. Dreampath will operate as a standalone company within Halma's Healthcare Sector, led by its current management team.

 

Marc Ronchetti, Group Chief Executive of Halma, commented: "Dreampath is a high-quality business in a growing area of diagnostics, driven by increasing demand for better healthcare, more testing alongside new treatments, and rising rates of chronic disease as populations age. It strengthens our Healthcare Sector by adding complementary capabilities and broadening our portfolio of technologies that support safer, more efficient and effective care. We are pleased to welcome Dreampath to Halma."

 

Pablo Jordan, CEO of Dreampath, said: "We are excited to join Halma at an important point in Dreampath's journey. We were looking for a long-term home that would value what makes Dreampath distinctive, support our people and culture, and help us accelerate our growth to continue protecting patients, sample by sample. Halma offers that combination of autonomy, ambition and support. We are pleased to become part of the Group and look forward to the opportunities ahead. We thank all employees and our shareholders for their support getting us here."  

 

For further information, please contact:

 

Halma plc

Marc Ronchetti, Group Chief Executive                              +44 (0)1494 721111                             

Carole Cran, Group Chief Financial Officer

Charles King, Co-Head of Investor Relations                     +44 (0) 7776 685948

Melanie Horton, Co-Head of Investor Relations                 +44 (0) 7554 013 396

 

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare                 +44 (0)20 3128 8100 / +44 (0)7817 458 804

 

A copy of this announcement, together with other information about Halma, is available at www.halma.com.

 

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

 

Its purpose defines the three broad market areas where it operates:

 

·      Safety

Protecting people, assets and critical infrastructure by addressing safety risks in public, commercial and industrial environments, and supporting a safer, more sustainable future.

·      Environmental & Analysis

Monitoring the environment and ensuring the quality and availability of life-critical resources, and enabling scientific research through advanced measurement, analysis and data transmission.

·      Healthcare

 

 

Meeting the growing demand for healthcare as populations age and chronic conditions rise, by supporting the discovery of new cures, the prevention, diagnosis and treatment of patient conditions, and enabling the delivery of safer, more efficient healthcare.



It employs over 9,000 people in more than 20 countries, with major operations in the UK, Europe, the US and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

 

Halma has been named as one of Britain's Most Admired Companies for the past seven years.

 

For more information www.halma.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQRFMFTMTMMBPF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Half Year Results

14 hours, 57 minutes ago

Director Declaration

1 day, 12 hours ago

Trading Update

on 09/24/2026

Acquisition

on 09/02/2026

Halma PLC - Disposal

on 08/04/2026

5 min read